RxDoctor Payments Data

John Larson, MD

Family Medicine · Bremen, INNPI 1215932173

Payments from drug & device makers

$739in general payments, 2019–2025

Across 31 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medline Industries LP$114
  • Kerecis Limited$109
  • Smith+Nephew$97
  • Organogenesis Inc.$74
  • Integra Lifesciences Corporation$63
  • Derma Sciences, Inc.$39
  • plus $241 from 11 others

What the payments were for

  • Food & beverage$739100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$739 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$110,633
Medicare patients
205
Services billed
1,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide44$52,490
EliquisApixaban20$32,447
OzempicSemaglutide27$30,269
JardianceEmpagliflozin21$27,092
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$22,867
XareltoRivaroxaban23$22,800
JanuviaSitagliptin Phosphate21$21,557
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$19,415
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,871
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,717
Humalog Kwikpen U-100Insulin Lispro16$5,897
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,289
SynthroidLevothyroxine Sodium29$3,150
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$2,929
Metoprolol Succinate117$1,283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$25$22,80023 claims
AbbVieSynthroid$12$3,15029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Bremen

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →